摘要登革病毒是黄病毒科的单链 RNA 包膜病毒，是导致登革热、登革出血热及登革休克综合征的病原体。登革病毒主要通过埃及伊蚊和白纹伊蚊在全球热带和亚热带地区广泛传播。目前已有数个登革疫苗进入临床试验阶段，赛诺菲巴斯德（Sanofi Pasteur）的四价重组疫苗（CYD）是现在唯一已在部分南亚和美洲国家上市的登革疫苗产品。但该疫苗仍有免疫保护不平衡、增加5岁以下儿童的重症率等缺陷。因此研究可诱导均衡持久的抗登革病毒保护性免疫应答的疫苗仍是我们现在所面临的挑战。本文就登革病毒的免疫机制及疫苗研发过程中遇到的机遇与挑战做一简要综述并对开发新型登革疫苗做出展望。

abstractsDengue virus(DENV)is an enveloped single positive-stranded RNA virus that belongs to the Flaviviridae family. It is the cause of dengue fever,life-threatening dengue hemorrhagic fever and den-gue shock syndrome. Aedes aegypti and Aedes albopictus are responsible for the wide transmission of DENV in tropical and subtropical regions throughout the world. Currently,there have been several dengue vaccines entering clinical trials,including the Sanofi Pasteur chimeric yellow fever dengue tetravalent vaccine (CYD),which has been licensed for use in some countries. However,CYD does not provide adequate pro-tection against all four serotypes of DENV and induces severe dengue diseases in young and seronegative vac-cine recipients. Therefore,a more efficacious dengue vaccine is still needed. Here,we reviewed the oppor-tunities and challenges for the development of dengue vaccines.